Transcend’s PTSD therapy shows potential in Phase II trial
The company’s Phase II IMPACT-1 trial found treatment with TSND-201 was generally safe and well tolerated.

The company’s Phase II IMPACT-1 trial found treatment with TSND-201 was generally safe and well tolerated.
In the fast-paced world of medical communications, understanding reuse rights and copyright compliance is critical, particularly in today’s ever-evolving technological landscape.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
MWC Barcelona 2025: Maximizing 5G network value in the age of AI
Driving bioscience innovation: How Teesside University empowers industry breakthroughs
The AI advantage in discovering new medicines
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline